MX2022000452A - Proteína de fusión del anticuerpo eta y trampa de tgf-¿ y composición farmacéutica y aplicación de la misma. - Google Patents
Proteína de fusión del anticuerpo eta y trampa de tgf-¿ y composición farmacéutica y aplicación de la misma.Info
- Publication number
- MX2022000452A MX2022000452A MX2022000452A MX2022000452A MX2022000452A MX 2022000452 A MX2022000452 A MX 2022000452A MX 2022000452 A MX2022000452 A MX 2022000452A MX 2022000452 A MX2022000452 A MX 2022000452A MX 2022000452 A MX2022000452 A MX 2022000452A
- Authority
- MX
- Mexico
- Prior art keywords
- tgf
- trap
- fusion protein
- pharmaceutical composition
- eta antibody
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1841—Transforming growth factor [TGF]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/495—Transforming growth factor [TGF]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2869—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against hormone receptors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/32—Fusion polypeptide fusions with soluble part of a cell surface receptor, "decoy receptors"
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Zoology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Gastroenterology & Hepatology (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Toxicology (AREA)
- Endocrinology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Microbiology (AREA)
- Pulmonology (AREA)
- Neurology (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Mycology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Cell Biology (AREA)
- Peptides Or Proteins (AREA)
Abstract
Se proporciona una proteína de fusión de un anticuerpo ETA y una Trampa de TGF-ß. También se proporciona una composición farmacéutica de la proteína de fusión del anticuerpo ETA y la Trampa de TGF-ß. Se proporciona además un método para tratar, prevenir o mejorar uno o más síntomas de hipertensión arterial pulmonar, hipertensión pulmonar, fibrosis pulmonar o fibrosis cardiovascular mediante el uso de la proteína de fusión del anticuerpo ETA y la Trampa de TGF-ß.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201910645466.XA CN112239507A (zh) | 2019-07-17 | 2019-07-17 | ETA抗体与TGF-β Trap的融合蛋白质,以及其药物组合物和应用 |
PCT/CN2020/101857 WO2021008519A1 (zh) | 2019-07-17 | 2020-07-14 | ETA抗体与TGF-βTrap的融合蛋白质,以及其药物组合物和应用 |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2022000452A true MX2022000452A (es) | 2022-04-25 |
Family
ID=74167347
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2022000452A MX2022000452A (es) | 2019-07-17 | 2020-07-14 | Proteína de fusión del anticuerpo eta y trampa de tgf-¿ y composición farmacéutica y aplicación de la misma. |
Country Status (11)
Country | Link |
---|---|
US (1) | US20220265771A1 (es) |
EP (1) | EP4008731A4 (es) |
JP (1) | JP2022540918A (es) |
KR (1) | KR20220035155A (es) |
CN (2) | CN112239507A (es) |
AU (1) | AU2020313155A1 (es) |
BR (1) | BR112022000883A2 (es) |
CA (1) | CA3147687A1 (es) |
MX (1) | MX2022000452A (es) |
TW (1) | TW202108630A (es) |
WO (1) | WO2021008519A1 (es) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112961250B (zh) * | 2021-03-01 | 2023-06-06 | 长春金赛药业有限责任公司 | 抗体融合蛋白及其应用 |
CN115141276A (zh) * | 2021-03-31 | 2022-10-04 | 鸿运华宁(杭州)生物医药有限公司 | 一种能与人内皮素受体特异性结合的抗体及其在糖尿病肾病和慢性肾病治疗中的应用 |
CN115490770A (zh) * | 2021-06-17 | 2022-12-20 | 鸿运华宁(杭州)生物医药有限公司 | 一种能与人eta和人cd3结合的双特异性抗体及其应用 |
Family Cites Families (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
JPS6023084B2 (ja) | 1979-07-11 | 1985-06-05 | 味の素株式会社 | 代用血液 |
US4331647A (en) | 1980-03-03 | 1982-05-25 | Goldenberg Milton David | Tumor localization and therapy with labeled antibody fragments specific to tumor-associated markers |
US4640835A (en) | 1981-10-30 | 1987-02-03 | Nippon Chemiphar Company, Ltd. | Plasminogen activator derivatives |
US4737462A (en) | 1982-10-19 | 1988-04-12 | Cetus Corporation | Structural genes, plasmids and transformed cells for producing cysteine depleted muteins of interferon-β |
US4518584A (en) | 1983-04-15 | 1985-05-21 | Cetus Corporation | Human recombinant interleukin-2 muteins |
US4496689A (en) | 1983-12-27 | 1985-01-29 | Miles Laboratories, Inc. | Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer |
US4751180A (en) | 1985-03-28 | 1988-06-14 | Chiron Corporation | Expression using fused genes providing for protein product |
DE3675588D1 (de) | 1985-06-19 | 1990-12-20 | Ajinomoto Kk | Haemoglobin, das an ein poly(alkenylenoxid) gebunden ist. |
US4935233A (en) | 1985-12-02 | 1990-06-19 | G. D. Searle And Company | Covalently linked polypeptide cell modulators |
US4791192A (en) | 1986-06-26 | 1988-12-13 | Takeda Chemical Industries, Ltd. | Chemically modified protein with polyethyleneglycol |
US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
US5011912A (en) | 1986-12-19 | 1991-04-30 | Immunex Corporation | Hybridoma and monoclonal antibody for use in an immunoaffinity purification system |
US5262522A (en) | 1991-11-22 | 1993-11-16 | Immunex Corporation | Receptor for oncostatin M and leukemia inhibitory factor |
AU678787B2 (en) | 1992-10-23 | 1997-06-12 | Immunex Corporation | Methods of preparing soluble, oligomeric proteins |
US5457035A (en) | 1993-07-23 | 1995-10-10 | Immunex Corporation | Cytokine which is a ligand for OX40 |
US6133426A (en) | 1997-02-21 | 2000-10-17 | Genentech, Inc. | Humanized anti-IL-8 monoclonal antibodies |
WO1998056915A2 (en) | 1997-06-12 | 1998-12-17 | Research Corporation Technologies, Inc. | Artificial antibody polypeptides |
GB9722131D0 (en) | 1997-10-20 | 1997-12-17 | Medical Res Council | Method |
US6210924B1 (en) | 1998-08-11 | 2001-04-03 | Amgen Inc. | Overexpressing cyclin D 1 in a eukaryotic cell line |
GB9928787D0 (en) | 1999-12-03 | 2000-02-02 | Medical Res Council | Direct screening method |
GB0025144D0 (en) | 2000-10-13 | 2000-11-29 | Medical Res Council | Concatenated nucleic acid sequences |
US20030133939A1 (en) | 2001-01-17 | 2003-07-17 | Genecraft, Inc. | Binding domain-immunoglobulin fusion proteins |
US20040202995A1 (en) | 2003-04-09 | 2004-10-14 | Domantis | Nucleic acids, proteins, and screening methods |
UA109888C2 (uk) * | 2009-12-07 | 2015-10-26 | ІЗОЛЬОВАНЕ АНТИТІЛО АБО ЙОГО ФРАГМЕНТ, ЩО ЗВ'ЯЗУЄТЬСЯ З β-КЛОТО, РЕЦЕПТОРАМИ FGF І ЇХНІМИ КОМПЛЕКСАМИ | |
MX2013013752A (es) * | 2011-05-25 | 2014-08-01 | Intermune Inc | Pirfenidona y tratamiento anti-fibrotico en pacientes seleccionados. |
CN104371019B (zh) * | 2013-08-13 | 2019-09-10 | 鸿运华宁(杭州)生物医药有限公司 | 一种能与glp-1r特异性结合的抗体及其与glp-1的融合蛋白质 |
US9750761B2 (en) * | 2014-05-21 | 2017-09-05 | University Of Rochester | LDH inhibitors as treatment for fibrosis and fibrotic-related disorders |
CN105669863B (zh) * | 2014-12-05 | 2019-09-13 | 鸿运华宁(杭州)生物医药有限公司 | 一种能与人内皮素受体特异性结合的抗体及其应用 |
CA2996996A1 (en) * | 2015-08-31 | 2017-03-09 | National Research Council Of Canada | Tgf-.beta.-receptor ectodomain fusion molecules and uses thereof |
CN116425875A (zh) * | 2015-09-18 | 2023-07-14 | 安驰肿瘤公司 | 治疗性cd47抗体 |
PT3356413T (pt) * | 2015-10-01 | 2022-04-04 | Potenza Therapeutics Inc | Proteínas de ligação a antigénio anti-tigit e métodos de utilização das mesmas |
CN107987162A (zh) * | 2016-10-27 | 2018-05-04 | 鸿运华宁(杭州)生物医药有限公司 | Etar抗体,其药物组合物及其应用 |
WO2018035119A2 (en) * | 2016-08-16 | 2018-02-22 | University Of Maryland, Baltimore | Methods of treating cancer using bifunctional molecules that target growth factors |
-
2019
- 2019-07-17 CN CN201910645466.XA patent/CN112239507A/zh active Pending
-
2020
- 2020-07-14 BR BR112022000883A patent/BR112022000883A2/pt unknown
- 2020-07-14 JP JP2022502538A patent/JP2022540918A/ja active Pending
- 2020-07-14 MX MX2022000452A patent/MX2022000452A/es unknown
- 2020-07-14 EP EP20840563.9A patent/EP4008731A4/en active Pending
- 2020-07-14 KR KR1020227004194A patent/KR20220035155A/ko unknown
- 2020-07-14 CN CN202080051495.4A patent/CN114127126B/zh active Active
- 2020-07-14 WO PCT/CN2020/101857 patent/WO2021008519A1/zh unknown
- 2020-07-14 CA CA3147687A patent/CA3147687A1/en active Pending
- 2020-07-14 AU AU2020313155A patent/AU2020313155A1/en active Pending
- 2020-07-14 US US17/627,089 patent/US20220265771A1/en active Pending
- 2020-07-16 TW TW109124139A patent/TW202108630A/zh unknown
Also Published As
Publication number | Publication date |
---|---|
KR20220035155A (ko) | 2022-03-21 |
CN114127126B (zh) | 2024-08-09 |
US20220265771A1 (en) | 2022-08-25 |
EP4008731A1 (en) | 2022-06-08 |
CN112239507A (zh) | 2021-01-19 |
CN114127126A (zh) | 2022-03-01 |
BR112022000883A2 (pt) | 2022-03-08 |
CA3147687A1 (en) | 2021-01-21 |
WO2021008519A1 (zh) | 2021-01-21 |
JP2022540918A (ja) | 2022-09-20 |
EP4008731A4 (en) | 2023-07-19 |
TW202108630A (zh) | 2021-03-01 |
AU2020313155A1 (en) | 2022-02-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2022000452A (es) | Proteína de fusión del anticuerpo eta y trampa de tgf-¿ y composición farmacéutica y aplicación de la misma. | |
MX2020004571A (es) | Contorsbodies 2+1 biespecificos. | |
PE20200294A1 (es) | Anticuerpos que se unen especificamente a pd-1 y metodos de uso | |
EA201991577A1 (ru) | Новые антитела против рецептора трансферрина человека, способные преодолевать гематоэнцефалический барьер | |
AR101875A1 (es) | Proteína de unión a antígenos, bi-específicos del receptor anti-cgrp / receptor pac1 y usos de las mismas | |
PE20161439A1 (es) | Anticuerpos antagonistas dirigidos contra el peptido relacionado con el gen de calcitonina y metodos que usan los mismos | |
WO2020014473A8 (en) | TGFβ1 INHIBITORS AND USE THEREOF | |
MX2020011529A (es) | Un metodo para optimizar la expresion de anticuerpos. | |
MX2020010387A (es) | Metodos para detectar y cuantificar fgf21. | |
AR110967A1 (es) | Anticuerpos miméticos fgf21 y su uso | |
EA202091239A1 (ru) | Слитый белок на основе терапевтического фермента, имеющий новую структуру, и его применение | |
BR112021017801A2 (pt) | Anticorpos biespecíficos anti-vbeta17/anti-cd123 | |
CL2010000470A1 (es) | Anticuerpo que se une a efrina-b2 que comprende la region variable de la cadena liviana y pesada bvr-l1, hvr-l2, hvr-h1, hvr-h2 y hvr-h3; polinucleotido que codifica dicho anticuerpo; vector y celula huesped que comprende al polinucleotido; metodo para elaborar el anticuerpo, detectar efrina-b2; y uso de dicho anticuerpo. | |
EA202092420A1 (ru) | Антитело против pd-l1 и его применение | |
EA202090084A1 (ru) | Новый терапевтический ферментный слитый белок и его применение | |
JOP20210286A1 (ar) | جسم مضاد أحادي النسيلة يرتبط نوعياً مع gitr | |
EA202092849A1 (ru) | Моноспецифические и мультиспецифические антитела к tmeff2 и их применение | |
WO2020247929A8 (en) | High affinity anti-cd3 antibodies, and methods for their generation and use | |
CA3179819A1 (en) | Anti-sars-cov-2-spike glycoprotein antibodies and antigen-binding fragments | |
MX2023014458A (es) | Anticuerpos anti-ccr8 y usos de los mismos. | |
EA201790590A1 (ru) | Гуманизированное моноклональное антитело, ингибирующее ферментативную активность сосудисто-эндотелиальной липазы | |
MX2022007913A (es) | Composicion oral con dulzor aumentado. | |
CO6382184A2 (es) | Proteinas fijadoras de receptores de interleukinas-21 | |
EA201890187A1 (ru) | Рекомбинантные вирусоподобные частицы (vlp) с использованием протеина группового антигена (gag) вируса бычьего иммунодефицита | |
WO2020237092A3 (en) | Mmp-9 antibodies and methods of use thereof |